Natera Cancer Test Infringes Invitae Patent, Suit Alleges

Law360 (May 10, 2021, 8:01 PM EDT) -- Invitae, a genetic testing company based in San Francisco, has launched a lawsuit in Delaware federal court claiming that a non-invasive cancer detection test produced by rival Natera infringes an Invitae-owned DNA sequencing patent.

In a  complaint filed Friday, Invitae Corp. said  Natera Inc., based in Austin, Texas, was infringing U.S. Patent No. 10,604,799, which Invitae obtained earlier this year by way of an assignment agreement.

Specifically, the complaint said Natera's Signatera cancer diagnostic test is the infringing product. According to Natera, the test is a tumor DNA test that determines the level of cancer left in a patient.   

"Natera has...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!